| Dr Conrad Georg Hanstein, MD | |
|
3642 Camino De Las Lomas, Vista, CA 92084 | |
| (760) 707-7286 | |
| (866) 886-8914 |
| Full Name | Dr Conrad Georg Hanstein |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 3642 Camino De Las Lomas, Vista, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972544369 | NPI | - | NPPES |
| 34066900 | Medicaid | WI |
| Entity Name | Perham Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932113768 PECOS PAC ID: 2264327766 Enrollment ID: O20040216000182 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | St Francis Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891954574 PECOS PAC ID: 8123937992 Enrollment ID: O20040429000995 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Sanford Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699869875 PECOS PAC ID: 6800707100 Enrollment ID: O20040715001116 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Sanford Health Of Northern Minnesota |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770849697 PECOS PAC ID: 5597725168 Enrollment ID: O20041025000442 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | International Falls Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528041183 PECOS PAC ID: 1951365998 Enrollment ID: O20041118000626 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | International Falls Memorial Hospital Association |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1528041183 PECOS PAC ID: 1951365998 Enrollment ID: O20061104000465 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Perham Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1790799518 PECOS PAC ID: 2264327766 Enrollment ID: O20061104000612 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Sanford Health Network |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1497703045 PECOS PAC ID: 6800707100 Enrollment ID: O20061104000724 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | St Francis Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639162381 PECOS PAC ID: 8123937992 Enrollment ID: O20080303000129 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Windom Area Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841288644 PECOS PAC ID: 7113911272 Enrollment ID: O20110128000749 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | United Hospital District Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952307688 PECOS PAC ID: 6204158884 Enrollment ID: O20150422000058 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Entity Name | Carris Health - Redwood Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265914048 PECOS PAC ID: 7911259619 Enrollment ID: O20181129001082 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Conrad Georg Hanstein, MD 3642 Camino De Las Lomas, Vista, CA 92084-6639 Ph: (760) 707-7286 | Dr Conrad Georg Hanstein, MD 3642 Camino De Las Lomas, Vista, CA 92084 Ph: (760) 707-7286 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.
› Verified 7 days ago
Mary C. Cueva, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 326 S Melrose Dr Ste 200, Vista, CA 92081 Phone: 866-228-2236 Fax: 760-330-9331 | |
James V. Chabala, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 840 Townsite Dr, Vista, CA 92084 Phone: 760-630-2422 | |
Kristina Lepard, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 204 S Santa Fe Ave, Vista, CA 92084 Phone: 760-941-8888 | |
Mrs. Deisha Malones Wilson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Thunder Dr, Vista, CA 92083 Phone: 760-941-9002 Fax: 760-630-2515 | |
Ms. Juvy Escalante, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 204 S Santa Fe Ave, Vista, CA 92084 Phone: 760-473-0444 | |
Alexander Shaft, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 Cedar Rd, Vista, CA 92083 Phone: 760-806-5431 | |
Sophia Le Bradley, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 130 Cedar Rd, Vista, CA 92083 Phone: 760-806-5500 |